VEGFA and nonpapillary renal cell carcinoma: Decreased MHC-I expression associates with reduced PFS with avelumab (anti-PD-L1) plus axitinib (anti-vascular endothelial growth factor) in ccRCC (Motzer et al., 2020b), but the frequency and impact of loss of antigen presentation is undefined.